growth last delivered organic conference in QX second Dave, XX% our Thanks, X% joining comp, year. for top second XXXX, and where good challenging morning, call. year-on-year In quarter we grew of you for our of everyone. of us we Thank quarter a fiscal on
recent by drove equity that returning firms. been to strong levels. an in was therapeutic valuations for in the environment development biotech pre-COVID quarters, documented that sciences of high year One life and ago, well funding funding slowed spurred environment, vaccine the has incredibly smaller this It's COVID-related industry midst
was seen in very of In of of the customer in did delay pharma repeat as which and biotech divergence from reagent a instrument bulk is strong. base, versus still which cash QX, large biotech for customers. a did our orders, patterns orders, experience more priority our This we our not ordering year, becomes divergence end-market larger this certain conservation
funding Encouragingly, accelerated is growth within our the analytical continued run therapy the our rate which past trends in evident bio-pharma strong underlying research cell of continues, and strength and research during utilization environment the and that reagent activity proteomic tools. business, strong gene
details call. Also, ExoDx the of continue and our for order funnel growth uptake each later on in drivers the we additional I these instruments protein experience Prostate remains our and record analytical of test. provide full, will to
Before past President, for leadership best leading we who transitioning into over very wish discuss last Counsel The establishing years. years are and Brenda corporate nine I to functions Counsel retirement. the nine Bio-Techne's Executive has as results, General has Bohnen the Brenda new the Shane this I'd including her from welcome and General and Senior compliance our contributions made legal initiatives. of Brenda Vice in Shane the the the sustainability our X. company will first March President served like immeasurable, Vice role effective to Furlow be new team to
in digit from get the and quarter, let's geography Europe, rates end an QX. by market. quarter, our of the Now performance drove we of nicely sequentially with the recovering the into overview starting mid-single In growth specifics growth revenue experienced in
concerns implemented disruption year system a has energy operation. team around have Mainland that in recession tempered. funding. biotech severe of and to been the support minimal stability with also the nearly warehouse on As and more high new implementing as finished is a The to Dublin new ERP Europe We the year stronger Europe our progresses wave grew mid-teens and prices a end see markets last reminder, European in
lower QX. of North spend America is in biotech where the impact we biggest saw
and North are was than North XX% able goals. growth The that consumable in comp high with should year in low last digit and order on as of comps. that bio-pharma instrument prior become long-term single business run still year's digits remainder XX% activity the rate this double our America research still growth also in experienced growth a book greater underlying more America rates to and However, pass over and still we grow top overall. The line fiscal robust, biotech evident is suggests multiyear of
I want there. and dedication China. of Moving tremendous on the resilience our acknowledge to team to first
tools enable proteomic our Following the spatial lockdowns, discoveries continued research to reagents, biology this has analytical and solutions team in supply research scientific to market with multiple the Chinese geography.
COVID change government, our in strategy at the over within point. is Thankfully, does the China the in typically in this team team China to which and growth of to virulent are team, country, rapid the disruption produce five is strain Now following rapidly the our including Despite appear days. members was be QX. infected able impacted by not to COVID mid-single Chinese a by COVID, a XX% management spreading particularly digit back our to in within spread caused one XX still office
government's in subside in Bio-Techne markets a our believe sustainable zero-COVID After our fiscal return historic we XX-plus of China, full this a the strategy. our most accelerate rate waves Positioning to growth compared QX, region. end faster likely will percent of prior re-opening for the to in COVID
looking past shutdowns stimulus, pent-up government in proven see QX in strong we the XXXX Given pending and ahead. the trillion a demand RMBX.X
the XX%. increased our Sciences quarter revenue top segment from the Now starting comp let's platform, organic growth our Protein where of grew year a strong with segment, on X% for discuss last when
GMP to cell QX During and We portfolio challenging our organically therapy in year-on-year the gene a cell the year and and XX% gene XX% over in traction and despite business solutions our gain comp XXX%. where over therapy over quarter. of of cell workflow we grew we therapy within that, our last with still gene grew portfolio protein our almost is continued quarter,
state-of-the-art as during the commercial did the in a with customers culminating GMP in in Paul double remains The in team to the our roadmap track the additional facility business, menu quarter in number record months. an almost business. the facility this protein plans adding excellent proteins as produced St. to accounts in business growing GMP adding our to to for our place additional with GMP job quarter, Specific manufacturing produced well coming existing proteins on
and It's items, worth activity additional that are throughout sales driving RUO list portfolio small growing protein this frequently media, cross-selling molecules. noting also GMP of are as purchasing customers including proteins our
GMP workflows. self-renewal, the to storage key medicine regenerative differentiation in cell of and molecules as fields molecules, Speaking small our enable reprogramming, processes components small key these remain they are the therapy that
medicine that to substantial culture proteins in as growth are small media, molecules drastically GMP that driving focused molecule in of position our business as regenerative available capacity workflow we in our XX leadership manufacturing well regenerative in our small proteins that are are matrices The is portfolio GMP XX medicine, GMP Our specialty Bio-Techne. is growth UK. only GMP our from expanding so Bristol, in including profound cell
bulk teens Collectively, discuss in of antibodies RUO reagent enabling discoveries. part did during reagents in proteomic grew are let's core driven scientific the and to and QX the including small research portfolio proteins, from reagents, a biopharma Now RUO academic year, last contribution not which strong by our in of customers, that key of our quarter. molecules components repeat some orders the from biotech low
excluding run of research in that US. large We are very business healthy, performance reagent rate these the remains encouraged orders, our very especially the
includes We small of portfolio. reagents, to proteins, variations now molecule research in catalog continue growing XXX,XXX our expand which over antibody X,XXX a
high tracking portfolio with small the molecule to Initial during the enabling we very These when mitochondria Plus, lot used of dyes, small and fluorescent gives in reception with the selling MitoBrilliant at the for short RNA. labeling live detects a was base quarter. expanded and extremely single quarter, of high fixed the dyes, RNA the RNAscope example, fluorescent our initial dyes launch level production in cell with For resolution our co-detection of launch strong out cells. these new and the
our delivered the growth to tools, team low analytical the ProteinSimple where performance of on Moving single-digit branded in quarter. the
second in we year, year-on-year vaccine in quarter prior a antibody by for adoption particularly strong the strong of nearly comp and of Here, prior manufacturers driven the faced Maurice therapeutic period. XX% monoclonal among
over growth biologics, multiplex customers consumer immunoassay fully biopharma growth, delivered and solutions of our rapid and blots in the fully become academic to Western processes. installed portfolio is automated a years as few strong base leading our past The we ingrained
environment We are full, three very very across all in has funnel a including our funding that Maurice the encouraged for platforms instrument although order length the cycle. a biotech of the remains level Biologics instrument, record closing our
with customerized turning its biopharma use in ability quantitative replacement is to is Simple than and as anther blots for signaling and Western to research to and sample an quantify growth resonate the and the alternative Simple the Western markets. out with Western complex of targeted is with like to solution continues application system blot out to tolerant leading and in applications automate much instrument development. end system's protein our This the driving the degradation the immunoassay automated expanded system's identify usage in a Western be drug in lead ability studies, process academic more platform. intracellular proteins lysates, samples an time-consuming cumbersome to
the We strategies these are actively market implementing educate on to marketing applications. additional
at we officially XX, Conference. January Flex WCBA platform, Maurice our the biologics next-generation On launched
Maurice, XXXX. since As have in a of we adoption reminder, the seen tremendous its launch
an in protein cartridge-based and identity provide driving easy-to-use for With platform. robust the purity system's the instrument to five minutes ability demand in charge
$XXX into Maurice into in a where other exchange expand fractionation is to MauriceFlex new or icIEF separated in charge Flex characteristics. ion methods, capabilities, of instrument. capabilities based expands and new their labor-intensive Maurice on using mixture be allows mass addresses Fractionalization This market. differences to to front-end is the application on a components us sample step including adding fractionalization size, challenges the spectrometry, legacy chromatography. million time-consuming analyzed these
academic continue Now draw sub-picogram multiplexing our system footprint from attention and an cost immunoassay increased Ella’s Ella. on smaller and branded advantages sensitivity, SimplePlex researchers. for bio-pharma to update ease-of-use
trends As a our new state-of-the-art to we product room of cartridge and cartridges to increases adds now grow, manufacturing year. and space facility robust, current facility cartridge and meet per installed forecasted This laboratory, and new placements and base X,XXX XXX,XXX utilization remain to systems continues nearing capacity clean demand. manufacturing innovation opened Ella
opportunities into completed well Connecticut so prepare and exist Wallingford, No nascent platform. clinical successfully both as audit Ella other ICL discovery XXXX initial someday. diagnostics of diagnostics. ISO our biomarker instrument largest the platform also that is the inroads across tool large facility We and to our possibly for make the works we
closed Rounding interest well discuss in as out with Namocell our this team business. the we and we instrument dispensing and pleased our growing acquisition are XXXX, Namocell, let's the Recall the progress that as of and integrating made the on we in technology separation July platform. platforms, now novel single cell have
publication workflow low-pressure and maximize Cells, dispensing The cell or nature Namocell the study cloning single-cell using HPSC Stem that protocols. Namocell’s using rapid cloning workflow Pluripotent and dispensing microfluidic Human During single-cell a a featured the viability in quarter, which outlines gentle for ensures and technology, cells. platform robust was isolation of scale
and the platform We this future the instruments potential early are over see realizing stages having Namocell a of shipped XXX bright in to-date. the of technology, for
let's grew Now X% revenue where shift quarter. by we segment organically Diagnostics and to Genomics in the
discussion our a and the with diagnostics test. of start cancer of continued ExoDx business our molecular adoption prostate Let's
ExoDx patient the the revenue to quarter, strengthened the community favorable with impact of XXX% consecutive recommendations, the XX% quarter. and only LCD, to quarter patients the not five test combination the a a decision, as a sustained in commercial to emphasizes tests business. and also fourth over of our urology over the coverage reformed momentum marketing drive team Medicare prostate adherence for the team of volume increased that our identify biopsy, message well but contractor driven four During has tool biopsy number right of local to the as reconsidered delivered expanded The in record is as grew
in We ExoDx the tests key of and in trends across number records which we strong quarter. for number including ordering of doctor set over are the ordered indicators prostate the doctors all new seeing average per the of number the test, performance the track doctors,
a have reimbursement years drive among we plan positioned private a growth and US, test to veteran who We the by this coverage least expand in our doctors penetration continue community. With once decisions urologists the favorable game of strong than of XX% beyond. the also at to test in payer less executive and the the used hired redesigned remainder fiscal of for with within the potential business Xx, to are the XXXX for usage the current
with Continuing molecular diagnostics.
Asuragen carrier continue genetic and branded double-digit. screening kits to oncology grow
more deliver Nanopore carrier Oxford designed the with partnership reproductive to to During Asuragen develop and assays and reliable a health accurate quarter, for Technologies announced screening. options
Oxford a single capabilities any-read variance sequence length combines workflow sequencing and both and in decipher in conventional identify The to Nanopore's genetic sequencing genes single hard to genes system. a PCR collaboration Asuragen's using long-range
business, biology digits biotech similar as spatial in Protein Our to mid-single market branded provided softer a some quarter ACD, Sciences. the headwinds grew
revenue customers, Our demand. business professional transition ACD's service proxy for services leveraging making strong strength quarter assay biomarker increased Historically, discovery service business nearly capabilities future accounts XX% as into product had a a for eventually product pharma year-on-year. the in assay
We in recently our cell and single RNA the expanded RNAscope of RNA, same new with including our resolution. microRNA enabling sub-cellular using section biomarkers small ACD simultaneous fluorescent dyes, RNAs or small launch Plus Vivid three portfolio at the with together of tissue target regulatory detection the RNA
regulatory function quantify for and safety. to of tool new cellular RNAscope Plus which therapy is efficiency in changes expression gene in response provides valuable gene introduction a and RNAs, the essential optimization with researchers to
note, would positive saw offered response. through services where initially was overwhelmingly spatial RNAscope an professional assay I biology's Plus customer it
low we reagents diagnostic the experienced growth timing order handful in quarter. Lastly, and single-digit customers business impacted our of among a controls as
this in mid-single positions and remains returning growth our the products plus favorable at business is testing demand of increasing. XX-month pipeline controls additional to environment, for diagnostic for This a patients physicians, With their growth. macro strong future reagents diagnostic basis, a Looking trailing on digits.
and long-term remain the proteomic funding continues created the tailwinds cell health the portfolio environment strength, remain supporting future research, optimistic on dynamic biopsies biology more and deliver the liquid our to and to as in full impact team scientific spatial long-term intact, The to and capitalize suited despite we temporary our and summary, In care. The successfully business. on firmly current China, in shape place execute therapies, our and of and they team ideally navigate ever strategy challenges is targets. this these COVID our at opportunities than environment and to biotech science is the life gene by well-positioned grow research
With call I'll the turn that, to over Jim.
